W

ith biotech’s constant parade of venture financings, Wall Street debuts, and nine-figure buyouts, it’s easy to forget that constant boom wasn’t always the norm.

It all kicked off in 2013, when a surge in investor optimism made it unprecedentedly easy for biotech companies to go public, which sparked a rush of VC dollars and created a virtuous cycle that lined the pockets of investors and set the stage for future initial public offerings.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting: this is my very first visit, having just subscribed to STAT, and the first article I click on is interrupted, first, by an ad (expected), then asking to upgrade if I want to finish the article. Thank you for inviting me to the top of the hierarchy, but “No, thanks!”

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.